Related references
Note: Only part of the references are listed.Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth
Melanie Bruchard et al.
NATURE MEDICINE (2013)
Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1's inhibitory effect on Bak
C. Wang et al.
ONCOGENE (2012)
Why not treat human cancer with interleukin-1 blockade?
Charles A. Dinarello
CANCER AND METASTASIS REVIEWS (2010)
5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
Julie Vincent et al.
CANCER RESEARCH (2010)
NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?
Jurg Tschopp et al.
NATURE REVIEWS IMMUNOLOGY (2010)
IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway
Lin Wang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors
Francois Ghiringhelli et al.
NATURE MEDICINE (2009)
Immunogenicity of anthracyclines: moving towards more personalized medicine
Lionel Apetoh et al.
TRENDS IN MOLECULAR MEDICINE (2008)
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
NATURE MEDICINE (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Share Paper
